Ekso Bionics Holdings, Inc. (EKSO), a leading company in the field of exoskeleton technology for medical use, reported a dip in sales for the third quarter of 2024 but remains optimistic about future growth. The company's quarterly sales fell to $4.1 million from $4.6 million in the third quarter of the previous year.
Despite the decrease in sales, Ekso Bionics achieved a gross profit of $2.2 million with a gross margin of approximately 53.5%. The company also marked a significant milestone with the approval and reimbursement of its first CMS claim for the Ekso Indego Personal device, which is anticipated to improve access for spinal cord injury patients.
Key Takeaways
- Ekso Bionics' Q3 sales declined to $4.1 million from $4.6 million in Q3 2023.
- The company sold 33 EksoHealth devices, with strong international performance, especially in Europe and APAC.
- Gross profit stood at $2.2 million with a gross margin of approximately 53.5%.
- Ekso Bionics achieved a significant milestone with the CMS claim approval for the Ekso Indego Personal device.
- The company is optimistic about future growth, with a solid backlog and strong demand in Europe.
Company Outlook
- Management remains optimistic about future growth, citing strong demand and an increasing pipeline of opportunities.
- Focus on improving operational efficiencies and enhancing collaboration with healthcare providers.
- Exploring expansions into neurological conditions through partnerships with research hospitals.
- Aiming to normalize procurement cycles with Integrated Delivery Networks (IDNs).
Bearish Highlights
- Quarterly sales decreased from the same period last year.
- Some enterprise accounts have delayed purchases due to macroeconomic uncertainties.
- Only one CMS claim reimbursement received, with others requiring additional information.
Bullish Highlights
- International sales reached record levels, particularly in Europe.
- Revenue from personal health product sales nearly doubled from Q2 to Q3.
- Strong pipeline for future placements with over a dozen devices in backlog.
Misses
- Revenue for the first nine months of 2024 decreased to $12.8 million from $13.4 million in the same period of 2023.
- Net loss of $7.9 million, though an improvement from a $12 million loss in the prior year.
Q&A Highlights
- Management discussed efforts to expand legal indications for neurological conditions.
- Emphasized the importance of the initial reimbursement approval for the Ekso Indego Personal device.
- Expressed confidence in the company's scalable commercial strategy and commitment to patient engagement.
In conclusion, Ekso Bionics Holdings, Inc. faces some challenges in the current economic environment, but the approval and reimbursement for the Ekso Indego Personal device and a strong international presence provide a basis for future growth. The company is working on expanding its product indications and strengthening collaborations to improve market penetration and patient access to its innovative exoskeleton technology.
InvestingPro Insights
Ekso Bionics Holdings, Inc. (EKSO) presents a mixed financial picture that aligns with the recent quarterly report. According to InvestingPro data, the company's revenue for the last twelve months as of Q2 2024 stood at $18.16 million, with a notable revenue growth of 15.63% over the same period. This growth trend is encouraging, especially when considering the recent quarterly dip in sales reported in the article.
An InvestingPro Tip highlights that net income is expected to grow this year, which could signal a potential turnaround from the reported net loss of $7.9 million in the first nine months of 2024. This projection aligns with the company's optimistic outlook and focus on operational efficiencies mentioned in the article.
Another relevant InvestingPro Tip indicates that EKSO is quickly burning through cash. This information adds context to the company's financial situation and underscores the importance of the recent CMS claim approval for the Ekso Indego Personal device, which could potentially improve cash flow through increased sales and reimbursements.
It's worth noting that EKSO's market capitalization stands at a modest $24.39 million, reflecting its current position as a small-cap company in the medical technology sector. This valuation suggests that investors are cautiously optimistic about the company's future prospects, balancing the potential of its innovative exoskeleton technology against the current financial challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into EKSO's financial health and market position. These additional tips could be particularly valuable for understanding the company's growth potential in the context of its recent performance and future outlook.
Full transcript - Ekso Bionics Holdings Inc (EKSO) Q3 2024:
Operator: Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call. At this time, all participants are in the listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Matt Steinberg, Finn Partners. Thank you. You may begin.
Matt Steinberg: Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; and Jerome Wong, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter ended September 30th, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements include statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with Ekso's businesses, please see its filings with the Securities and Exchange Commission. Ekso disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise. Any forward-looking statements made on this call speak only as of the date of this call. I will now turn the call over to Ekso Bionics’ Chief Executive Officer, Scott Davis.
Scott Davis: Thank you, Matt. The third quarter reflected a period of transition in progress, particularly within our personal-line of EksoHealth devices. Notably, in August, the approval and reimbursement of the initial CMS claim for our Ekso Indego Personal, represented a significant milestone for Ekso and importantly, patients with spinal cord injuries. After CMS established pricing determination for our Ekso Indego Personal in April, we immediately executed our field communication strategy to ensure that all targeted health care providers were made aware of the new CMS access and coverage policy that could impact thousands of Medicare and Medicaid patients living with a spinal cord injury. Additionally, we've been working closely with our extensive network of neurorehabilitation centers across the country, focused on education efforts on appropriate patient selection, screening, trialing, onboarding and skills training for patients prescribed an Ekso Indego Personal for both at home and in community settings. I also want to highlight the success we've had with investing in various digital marketing programs and strategies designed to raise product and policy awareness, which have resulted in an influx of new qualified leads. Additionally, we continue to develop and evolve our educational access resources to support prescribing health care providers in navigating through the insurance process efficiently and effectively. We remain committed to enhancing our collaboration with health care providers by ensuring that our innovative solutions meet their needs and by streamlining our processes with their feedback. I want to emphasize that this is a program that takes time to build. We're excited to see that across all targeted sectors, our pipeline is steadily increasing which we believe will enable us to scale this program over time. With multiple claims now submitted through our DME to Medicare, we will continue to focus our efforts on continued customer education to improve process efficiencies. We are actively engaging with new potential customers. This not only enhances our understanding of their needs, but also allows us to showcase the benefits of the Ekso Indego Personal device. We are committed to expanding access to our innovative Ekso Indego Personal technology and empowering more qualified individuals to achieve greater mobility and independence. We look forward to providing updates on our continued work with the SCI community and eventually individuals with neurological conditions who could potentially benefit from our technology once we're able to obtain the necessary indications. Now I will share an overview of our third quarter performance. We generated quarterly sales of $4.1 million and sold 33 EksoHealth devices in the third quarter of 2024. US sales were affected by fluctuations in procurement cycles for our integrated delivery network, or IDN, customers that have persisted since the start of 2024. This was compounded by several customers delaying capital purchases into the fourth quarter and into early 2025. However, our demand and pipeline for EksoHealth products remain strong and we're focused on delivering our innovative devices to individual clinics and hospitals, while expanding our global customer base. We believe our expanding network of leading neurorehabilitation centers recognizes the clinical and economic benefits of our innovative EksoNR device. Currently, EksoNRs are deployed in 9 of the top 10 rehabilitation centers in the United States, which we believe is an indicator that our technology is becoming a standard-of-care for lower extremity neuro rehabilitation. We plan to leverage our strong reputation to drive growth for both our EksoNR and our Ekso Indego therapy devices. As we continue to strengthen our distribution network and expand our pipeline of opportunities, we remain confident in our ability to grow our presence among neurorehabilitation centers and enhance patient outcomes. Internationally, demand remains strong, mirroring our robust performance in the first half of the year. Sales in Europe achieved record levels in the quarter as neurorehabilitation centers in the region are adopting our potentially life-changing technology. In addition to placing more devices worldwide, we also expanded our international distribution network, which has allowed us to achieve greater operating leverage in foreign markets, which we believe positions us well for continued success on a global scale. As we look ahead, we are committed to further developing our relationships with our IDNs to secure larger multi-unit capital contracts across North America. This initiative is a key component of our ongoing commercial strategy to expand our market presence, and we are optimistic about our future prospects and the growing pipeline of potential deals. Now I'd like to provide a brief update on our Industrial segment, EksoWorks. In the third quarter, sales of Ekso's EVO exoskeleton were impacted by labor strikes in US manufacturing industries. Nonetheless, we are committed to raising awareness about the benefits that EVO offers for workers engaged in demanding overhead tasks, including reduced fatigue, increased productivity and fewer workplace injuries. EVO is suitable for a range of industries, notably in automotive, aerospace, construction and renewable energy verticals and numerous other sectors where overhead work is necessary. Now shifting to our operations, where we continue to create more efficiencies throughout our business. Our improvements in supply chain and inventory management, along with efficiencies gained in production resulted in strong gross margins for the quarter despite a concentration of our revenue being sold in Europe, which reflected lower ASPs, as is typical with distribution. Overall, we are pleased to have improved our operating margins in the quarter by reducing our operating expenses. In summary, this was a quarter of progress for Ekso Bionics, marked by the receipt of initial CMS claims reimbursement for our Ekso Indego Personal device and increased global demand for EksoNR. With our total product portfolio that has the potential to reach a large addressable market in excess of $13 billion across the continuum of care, we believe we are trending in the right direction for future growth. At this time, I'd like to turn the call over to our Chief Financial Officer, Jerome Wong, to review our third quarter financial results.
Jerome Wong: Thank you, Scott. We generated quarterly sales of $4.1 million in the third quarter of 2024 compared to $4.6 million for the third quarter of 2023. Gross profit for the third quarter of 2024 was $2.2 million representing a gross margin of approximately 53.5% compared to gross margin of 53.3% in the third quarter of 2023. The increase in gross margin was primarily driven by cost savings in supply chain and a reduction in service costs, partially offset by lower margin sales related to increased volume through distribution. Operating expenses for the third quarter of 2024 were $4.8 million compared to $5.4 million for the third quarter of 2023. The decrease was primarily due to lower headcount, discretionary payroll and consulting costs. Net loss applicable to common stockholders for the third quarter decreased to $2.1 million or $0.10 per basic and diluted share from a net loss of $3.4 million or $0.24 per basic and diluted share for the same period in 2023. Now turning to our financial results for the first nine months of 2024. Revenue was $12.8 million for the nine months ended September 30, 2024 compared to $13.4 million for the same period in 2023. We sold a total of 99 EksoHealth devices in the first nine months of 2024. Gross profit for the nine months ended September 30, 2024, was $6.8 million, representing a gross margin of approximately 53% compared to a gross margin of 50% in the third quarter 2023. The increase in gross margin was primarily driven by cost savings and supply chain and a reduction in service costs, partially offset by lower margin sales related to increased volume through distribution. Operating expenses for the nine months ended September 30, 2024, were $15 million compared to $18.4 million for the same period in 2023. The decrease was primarily due to lower headcount, discretionary payroll accounting, consulting and legal costs. Net loss applicable to common stockholders for the nine months ended September 30, 2024, was $7.9 million or $0.42 per basic and diluted share compared to a net loss of $12 million or $0.88 per basic and diluted share for the same period in 2023. Cash and restricted cash as of September 30, 2024, was $8.3 million compared to $8.6 million as of December 31, 2023. In September, we closed an underwritten public offering, resulting in net proceeds of approximately $5 million. Please see our Quarterly Report on Form 10-Q filed earlier today for further details regarding the quarter. Operator, you may now open the line for questions.
Operator: Thank you. We will now be conducting a question-and-answer session. [Operator Instructions] And our first question comes from RK, H.C. Wainright.
Swayampakula Ramakanth: Good morning Scott, Jerome.
Scott Davis: Hi, RK.
Swayampakula Ramakanth: A few questions from me. So it's good to see that you have 33 placements during the quarter. I'd like to know of these 33 placements, how many of them were ex-US because you are saying that the ex-US geographies are doing pretty good.
Scott Davis: Yes. correct. Approximately half of those were here in Europe and several of them in APAC. So the -- I would say the majority of those placements were outside of US. And within those devices, we had -- in terms of revenue, we had about 28% of revenue that was reflected by the personal product.
Swayampakula Ramakanth: Okay. Perfect. And then in terms of claims that you filed with CMS, you were saying that you are pretty much caught up with terms of filing. So is there a way you can give us the number in terms of how many have been filed and what percent of those files have been reimbursed.
Scott Davis: Sure. On the personal devices, I can give you a sense of this we've submitted multiple claims year-to-date, the majority of which happened in the third quarter. And to-date, our DME partner has received reimbursement on one claim. We've had two claims that have come back and required additional information for resubmittal. But in general, we almost doubled the sales of personal health products from Q2 to Q3. And we believe today, that represents as I said, about 20% of our sales for the quarter. I will say that the claims that we are submitting are taking some time to move through the reimbursement process.
Swayampakula Ramakanth: Okay. And then the last question from me is regarding the buying cycles of some of your customers. You were saying that some of the folks have been pushing. They're buying into fourth quarter of this year and first quarter of '25. So based on what you are seeing, what do you think is generally the backlog now in the sense that you have a lead but has not been filled because of their pushback? And is there a way for us to kind of figure out how that backlog is getting taken care of.
Scott Davis: Yes. In terms of backlog, we have ordered backlog that is on the books right now for Q4. I think the way to think about this is that we have continued strong demand in Europe. And as it relates to North America, this has been a bit of an off-cycle year for us with our IDNs. We had very strong sales in 2022 and 2023 relative to our IDN procurements. And 2024 remains impacted by being slightly off cycle with these customers in North America. However, we do believe that we're coming around again to renewal cycles, which we anticipate will positively impact us in 2025 and in Q4 as well. So we have a strong pipeline and demand, which support future growth on our enterprise segment as well as in our personal segment.
Swayampakula Ramakanth: Okay, thanks for taking all my questions.
Scott Davis: Yeah, you bet. Thank you.
Operator: And our next question comes from Ben Haynor, Lake Street Capital.
Ben Haynor: Good afternoon, gentlemen. Thanks for taking my questions. First off for me, just following up on the IDNs, have there been any I know you mentioned it being off cycle. But has there been any distraction for any reason due to the CMS reimbursement for the personal units and have folks weighted and try to take a look at maybe adding some Indego's to the clinics or anything like that? Are there any dynamics at play related to the personal units?
Scott Davis: Yes, that's a great question. In general, I would say the issue really isn't so much around distraction as it is, a lot of these enterprise accounts are lumpy, and we had absolute record sales in North America in 2023. We're having absolute record sales in Europe this year. So some of this is just really following procurement cycles. We have -- certainly in Q3 and in North America, we had multiple customers on the enterprise side that made the decision to delay their purchases to either Q4 or into 2025, just citing some macroeconomic uncertainties that they had perhaps even relative to politics.
Ben Haynor: Sure. Makes sense. And then Europe, obviously is a bright spot here. How much insight do you have into how the remainder of the year could look on that front? Should we expect international to be as strong in Q4 as it was in Q3? Or what's the right way to think about that to the extent you could share?
Scott Davis: Yes. Demand in Europe remains strong for us. We've also accumulated a solid backlog coming into the quarter there. So as we look at Europe in Q4, we believe that we will once again have a strong quarter there.
Ben Haynor: Okay. So the -- you don't have like a clear [put] (ph) backlog entering Q4, it's just as strong as it was maybe entering Q3.
Scott Davis: Yes. I'll say that we have -- coming into the quarter, we had -- at the end of Q3, we had more than a dozen devices in backlog at the end of Q3.
Ben Haynor: Okay. Great. That's helpful. And then on the legal expansion that you mentioned earlier in the more neurological conditions, is there anything that investors should be on the lookout for there? Is there kind of a time-line that you could speak to on any of these things?
Scott Davis: Yes, nothing definitive yet, but I will say that Ekso has a history of working very closely with some of the top neurological research hospitals and facilities in North America and throughout the world. And our clinical studies, which can often be quite expensive, particularly when you're looking at new FDA indications for use. We have been able to leverage those long-standing relationships with those centers. And with the new personal products with our Indego family of products, we've had significant interest from those research hospitals to engage in those studies to potentially expand indication for use for our Indego family of exoskeleton. So this is something that we are working on currently. And the time frame on these sorts of endeavors is somewhat undefined, but it certainly takes some time to be able to do this, and we're lucky to have partners who can help us because it really helps us to contain the expenses that are related to gaining those clinical trials.
Ben Haynor: Okay. Got it. And then lastly for me, just one point of clarification. You said 20% of the revenue was the personal product. I'm not sure if I caught that. Was that overall or was that for specific to the US or international or any caveat there?
Scott Davis: Yeah. So in general, our top-line total revenue for the quarter, approximately 20% of that, was directly related to our personal products.
Ben Haynor: Got it. Okay. That’s all I had gentlemen, thanks for taking the question.
Scott Davis: You bet. Thank you Ben.
Operator: Thank you. There are no further questions at this time. I would like to turn the floor back to Scott Davis for closing remarks.
Scott Davis: Okay. Thank you, Julian, and thank you to everyone for joining us today. In closing, we are pleased with the progress we made this quarter and the strides that we've made on both the reimbursement and the operational fronts. While we recognize that there is still work to be done, the initial reimbursement approval for our Ekso Indego Personal device marks an important milestone for us and the SCI community, enabling access for covered individuals at a fraction of the cost. We believe our ongoing collaboration with physicians and neurorehabilitation centers is vital to our success, and we are committed to providing the resources and educational support necessary to drive patient engagement. We believe that as more physicians become advocates for our devices, we will see a corresponding increase in submissions and approvals. In terms of our enterprise customers, we're optimistic about the future as procurement cycles with IDNs normalize in the near term. We remain focused on collaborating with our partners to ensure that we can meet demand and capitalize on the opportunities ahead. As we continue to expand our reach, we believe we are well equipped for sustainable growth ahead. And as a result of our scalable commercial strategy, we closed the quarter with a strong pipeline of future placements. Moving forward, we are enthusiastic about building upon this progress. Thank you for your continued support, and we look forward to updating you on our progress in the coming quarters.
Operator: Thank you. This does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.